A strategic area of expertise for Ceva , canine cardiology has benefited from substantial R&D investment. Among other things, this investment has allowed the Group to develop, for the very first time in veterinary medicine, a molecule that was previously...

strategic area of expertise for Ceva, canine cardiology has benefited from substantial R&D investment. Among other things, this investment has allowed the Group to develop, for the very first time in veterinary medicine, a molecule that was previously restricted to use in human cardiology: spironolactone.

More recently, Ceva was the first company proposing a combination of two actives (spironolactone and benazepril) for improving both the dogs quality of life and the treatment compliance.
End of 2013, Ceva reached a new step in its strategy of innovation in canine cardiology by acquiring the Sogeval company. With Sogeval joining the Ceva group, Ceva not only enlarged its product portfolio for canine Congestive Heart Failure (CHF) but also acquired new expertise in the development and the production of new drug formulations and innovative solutions for improving treatment compliance (e.g. clover scored shaped tablets for easy breaking ; “Délicament” concept”; …).

“Being a pioneer in Cardiology” …

  • 2007: Introducing a new high-performing treatment for heart failure: Prilactone®

The active substance in PRILACTONE®, spironolactone, blocks the actions of a hormone called aldosterone in the kidneys, heart and blood vessels. By preventing the action of aldosterone, spironolactone causes the kidneys to excrete salt and fluids, but retains potassium,in congestive heart failure . It also works on the heart and blood vessels and hence improves heart function

The European public assessment report on the product concludes:

"PRILACTONE is used to treat dogs that have congestive heart failure because of faulty heart valves. When the heart valves are faulty, the heart is not able to pump blood as efficiently as before. As a result, blood can accumulate in the veins and fluid can leak out into the tissues, leading to the heart being unable to deliver oxygen-rich blood to the body adequately. PRILACTONE® is used in combination with “standard therapy” (other heart medicines, including diuretic support where necessary)..

How has PRILACTONE® been studied?
PRILACTONE® has been studied in the laboratory, as well as in three studies in dogs with heart valve diseases, which were treated in various veterinary practices or clinics across Europe (‘clinical studies‘). In these clinical studies, the animal owners gave either PRILACTONE® tablets or placebo (dummy tablets without any active ingredient) to their dogs, once daily, at a dose of 2 mg/kg with food. PRILACTONE® tablets were given with food because this results in more of the active substance being absorbed from the tablets. All dogs also received ‘standard therapy’ (generally another medicine belonging to the group called ACE-inhibitors and if needed a diuretic). Treatment continued for up to 15 months.

What benefit has PRILACTONE® shown during the studies?
The results of the studies showed that dogs with congestive heart failure caused by faulty heart valves that were given PRILACTONE® tablets in addition to another heart medicine (‘standard therapy’), had a longer survival time than the dogs that received the standard therapy plus placebo tablets. In a long term study, the dogs treated with PRILACTONE® also showed less deterioration of their heart disease compared to the dogs which were treated only with ‘standard therapy’.

  • 2012: First company to propose a combination of two actives for a better treatment of dog CHF: Cardalis®

With its unique combination of two actives (benazepril/spironolactone), Cardalis® is the only drug that truly limits the harmful effects of angiotensin II and aldosterone responsible for vasoconstriction and heart remodeling, by blocking the permanent activation of the Renin Angiotensin Aldosterone System (RAAS) in dogs with HF. 
By limiting the onset of the disease symptoms, Cardalis® greatly contributes to improve the dog quality of life.

  • 2013: Building the largest product offer for dog CHF treatment

With the acquisition of Sogeval in 2013, Ceva completed its product portfolio with two new products (Nelio® and Libeo®) for better answering vet needs. Indeed Congestive Heart Failure in dogs as in humans requires a polytherapy adapted to the patient condition and disease stage.

Nelio® (benazepril 2,5 mg/5 mg for cats ; 5 mg / 20 mg for dogs)
Benazepril (ACEi) is a standard therapy for treating Heart Failure in dogs or Chronic Kidney Disease in cats. 
In dogs with moderate or severe congestive heart failure, Nelio® dogs (5mg/20mg) is prescribed alone or in association with other drugs (e.g. diuretics, spironolactone…). It blocks the production of angiotensin II and partially of aldosterone restoring vasodilation and slowing down cardiovascular remodeling.
In cats with CRF, Nelio® Cats (2,5mg/5mg) helps controlling kidney function by reducing protein losses and limiting arterial blood pressure.

Libeo® (furosemide 10 mg/40 mg)
Furosemide is widely prescribed in symptomatic patients as soon as fluid retention (e.g. in lungs with pulmonary oedema) happens due to cardiac decompensation. It directly acts on kidneys to stimulate fluid excretion. A strict monitoring of the dog health evolution and the prescription of a minimum effective dose are necessary to avoid possible side effects (hypovolemia, hypokalemia, acute renal failure…). With its clover shaped scored tablets, Libeo® (10mg/40mg) allows the vets to fine-tune the dose of furosemide and rapidly helps his patient while limiting possible side effects which happen with other diuretics available on the market .

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top